A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

Autor: Petr Zatloukal, Maria Blasinska-Morawiec, Sandra J. Meech, Jacek Jassem, Nick Thatcher, Christian Manegold, Rebecca J. Benner, N. van Zandwijk, Eng Huat Tan, A. Ingrosso, Piotr Serwatowski, Maciej Krzakowski, David Robert John Readett, Aleksandra Szczesna, J. S.-K. Au

Publikováno v: Annals of Oncology. 23:72-77

Background This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC). Patients and methods Chemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac4b644b42c5fb46097d8cebcd58d6a1
https://doi.org/10.1093/annonc/mdr030

The roles of smoking and cooking emissions in lung cancer risk among Chinese women in Hong Kong

Autor: Ignatius Tak-sun Yu, J. S. K. Au, Yuk-lan Chiu, Xiaorong Wang, Hong Qiu

Publikováno v: Annals of Oncology. 20:746-751

We conducted this case-control study to evaluate smoking effect on lung cancer conditional on the level of exposure to cooking emissions and to explore whether there is a joint effect of these two risk factors.We selected 279 newly diagnosed primary

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562890b503c25d3e59cf2158c689b27d
https://doi.org/10.1093/annonc/mdn699

Staging of nasopharyngeal carcinoma: suggestions for improving the current UICC/AJCC Staging System

Autor: A W M, Lee, J S K, Au, P M L, Teo, T W, Leung, D T T, Chua, W M, Sze, B C Y, Zee, S C K, Law, S F, Leung, S Y, Tung, D L W, Kwong, W H, Lau

Publikováno v: Clinical oncology (Royal College of Radiologists (Great Britain)). 16(4)

To evaluate the current UICC/AJCC Staging System for nasopharyngeal carcinoma and to search for ways of improving the system.This is a retrospective analysis of 2687 consecutive patients treated in five public centres in Hong Kong during the period 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::866273b699e2053ccc7883c288d1af22
https://pubmed.ncbi.nlm.nih.gov/15630856

Clinical and Genomic Phenotype of Brain Metastasis in Nasopharyngeal Carcinoma.

Autor: Peng YP; The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China., Yang S; Department of Radiotherapy and Minimally Invasive Surgery, The Cancer Center of The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China., He J; Department of Pathology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China., Liu Q; The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China., Li X; The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China., Kong FG; Department of Neurosurgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China., Wang SY; The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China., Liu Y; Department of Pathology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.

Publikováno v: Molecular carcinogenesis [Mol Carcinog] 2024 Nov 22. Date of Electronic Publication: 2024 Nov 22.

Characterizing and Targeting of BCL-2 Family Members in Nasopharyngeal Carcinoma.

Autor: Thai AA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia., Young RJ; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia., Bressel M; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia., Kelly GL; Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, Australia., Sejic N; Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, Australia., Tsao SW; School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China., Trigos A; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia., Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Solomon BJ; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.

Publikováno v: Head & neck [Head Neck] 2024 Oct 30. Date of Electronic Publication: 2024 Oct 30.